Phase I/II Comparison of Efficacy and Safety of BIBF 1120 and Sorafenib in Patients With Advanced Hepatocellular Carcinoma
Status:
Completed
Trial end date:
2016-10-12
Target enrollment:
Participant gender:
Summary
The study aim is to determine maximally tolerated dose (MTD) of BIBF 1120 in HCC
(hepatocellular cancer) and compare efficacy of BIBF 1120 to Sorafenib in HCC patients